Development of Zevalin and future prospect of radioimmunotherapy

DOI Web Site 1 Citations 6 References

Bibliographic Information

Other Title
  • ゼヴァリンの開発経緯と放射免疫療法の今後
  • ゼヴァリン ノ カイハツ ケイイ ト ホウシャ メンエキ リョウホウ ノ コンゴ

Search this article

Description

Zevalin, the first approved radioimmunotherapeutic agent for Non-hodgkin's lymphoma, is not only highly effective but also kind treatment even for elderly patients. In this review, we summarize development of Zevalin and future prospect of radioimmunotherapy (RIT), and introduce our candidate as a novel radioimmunotherapeutic agent for NSCLC treatment. Prospective selection of patients responds to RIT will be essential for approval in oncology.

Journal

  • Drug Delivery System

    Drug Delivery System 28 (3), 197-204, 2013

    THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM

Citations (1)*help

See more

References(6)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top